Dec 2, 2025
Epigene Labs today announced a major advancement in its AI-powered data curation platform, achieving a twentyfold increase in curated cancer omic profiles within the past year. This breakthrough brings the company’s total curated data catalog to nearly 2 million cancer molecular profiles, including over 600,000 patient-derived profiles spanning genomics, transcriptomics, and epigenomics.
This accomplishment positions Epigene Labs alongside the most advanced data-centric biopharma technology companies and marks a defining moment for the future of precision medicine.
Since its founding, Epigene Labs has focused on transforming fragmented public omic data into unified, richly annotated disease atlases that power oncology research and drug development. The company’s latest expansion reflects seven years of scientific innovation and engineering advances, culminating in a dramatic acceleration in both scale and productivity.
Over the past twelve months, Epigene Labs:
With this release, Epigene Labs is unveiling its first comprehensive mapping of the cancer research data of the predominant public omic data repository, NCBI’s Gene Expression Omnibus (GEO). This mapping covers 21 data elements, including information on:
Built on top of this foundational data, Epigene Labs’ disease atlases reach scales up to ten times larger than current industry references. These atlases enable multidimensional insights into cancer biology, spanning biomarker discovery, pathway analysis, tumor microenvironment characterization, and cross-disease comparisons.
The new data volume empowers Epigene Labs to support large-scale collaborations with leading biopharma organizations.
Key applications include:
The company is also preparing to launch an off-the-shelf data product line tailored to smaller biotechs and academic research groups.
Epigene’s curation framework generalizes seamlessly across therapeutic areas. The company is already conducting early explorations into immunology and neurology, leveraging the shared core metadata and sample descriptors that underpin its oncology platform.
“Reaching 2 million curated cancer omic profiles is a defining moment for Epigene Labs. It validates seven years of scientific rigor, strategic pragmatism, and relentless engineering. More importantly, it opens the door to a new era where disease biology can be explored at a level of resolution and scale that was previously out of reach. This breakthrough will accelerate precision medicine research and development in oncology, and beyond.” commented Akpéli Nordor, Co-founder and CEO of Epigene Labs.
Epigene Labs creates intelligence-augmenting solutions to accelerate precision oncology research and drug development.
By harnessing artificial intelligence and next-generation bioinformatics, its mCUBE platform integrates fragmented multi-omic datasets into comprehensive disease atlases with unprecedented depth and breadth. As a result, mCUBE has significantly impacted various R&D programs on immuno-oncology — often reducing months of research to mere days. Applications include target discovery, biomarker identification, and patient selection at leading cancer research institutes and biopharmaceutical companies.
Based in Paris and Boston, Epigene Labs was initially incubated at the Harvard Innovation Labs and later launched in France with the backing of prominent European investors.
